Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556355643> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2556355643 abstract "Objectives: To evaluate the long-term costs and effectiveness of adding the novel/group 5 drugs bedaquiline and linezolid to a background regimen (BR) of drugs for treating multidrug-resistant tuberculosis (MDR-TB), from a German healthcare payer perspective. Methods: A cohort-based Markov model was developed to simulate the incremental cost-effectiveness ratio (ICER) of bedaquiline + BR or linezolid + BR versus BR alone in the treatment of MDR-TB, over a 10-year time horizon. Efficacy was evaluated in quality-adjusted life-years (QALYs) and life-years (LY), using inputs from the C208 clinical trial for bedaquiline and from a German observational study for linezolid. Cost data were obtained from German Drug Directory costs (€/2015), published literature, and expert opinion. A 3% yearly discount rate was applied. Sensitivity analyses were conducted. Results: The total discounted costs and QALYs per patient were €85,575 and 5.95 for bedaquiline + BR and €80,460 and 3.91 for linezolid + BR, compared with €60,962 and 3.68 for BR alone. Both bedaquiline and linezolid were therefore associated with higher QALYs and higher costs than BR alone, with ICERs of €22,238 for bedaquiline and €87,484 for linezolid, versus BR. In a fully incremental analysis, bedaquiline + BR was the most cost-effective option at thresholds >€22,000/QALY gained. Conclusions: In Germany, the addition of bedaquiline or linezolid to BR would result in QALY gains over BR alone. Based on this analysis, bedaquiline is likely to be the most cost-effective drug for the treatment of MDR-TB when added to BR, at thresholds >€22,000/QALY." @default.
- W2556355643 created "2016-11-30" @default.
- W2556355643 creator A5003396504 @default.
- W2556355643 creator A5014465574 @default.
- W2556355643 creator A5080315218 @default.
- W2556355643 date "2016-09-01" @default.
- W2556355643 modified "2023-09-28" @default.
- W2556355643 title "Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany" @default.
- W2556355643 doi "https://doi.org/10.1183/13993003.congress-2016.pa2681" @default.
- W2556355643 hasPublicationYear "2016" @default.
- W2556355643 type Work @default.
- W2556355643 sameAs 2556355643 @default.
- W2556355643 citedByCount "0" @default.
- W2556355643 crossrefType "proceedings-article" @default.
- W2556355643 hasAuthorship W2556355643A5003396504 @default.
- W2556355643 hasAuthorship W2556355643A5014465574 @default.
- W2556355643 hasAuthorship W2556355643A5080315218 @default.
- W2556355643 hasConcept C112930515 @default.
- W2556355643 hasConcept C126322002 @default.
- W2556355643 hasConcept C141071460 @default.
- W2556355643 hasConcept C142724271 @default.
- W2556355643 hasConcept C2777975735 @default.
- W2556355643 hasConcept C2778980435 @default.
- W2556355643 hasConcept C2779489039 @default.
- W2556355643 hasConcept C2780544761 @default.
- W2556355643 hasConcept C2781069245 @default.
- W2556355643 hasConcept C2781413609 @default.
- W2556355643 hasConcept C2781414143 @default.
- W2556355643 hasConcept C3019080777 @default.
- W2556355643 hasConcept C523546767 @default.
- W2556355643 hasConcept C54355233 @default.
- W2556355643 hasConcept C71924100 @default.
- W2556355643 hasConcept C86803240 @default.
- W2556355643 hasConceptScore W2556355643C112930515 @default.
- W2556355643 hasConceptScore W2556355643C126322002 @default.
- W2556355643 hasConceptScore W2556355643C141071460 @default.
- W2556355643 hasConceptScore W2556355643C142724271 @default.
- W2556355643 hasConceptScore W2556355643C2777975735 @default.
- W2556355643 hasConceptScore W2556355643C2778980435 @default.
- W2556355643 hasConceptScore W2556355643C2779489039 @default.
- W2556355643 hasConceptScore W2556355643C2780544761 @default.
- W2556355643 hasConceptScore W2556355643C2781069245 @default.
- W2556355643 hasConceptScore W2556355643C2781413609 @default.
- W2556355643 hasConceptScore W2556355643C2781414143 @default.
- W2556355643 hasConceptScore W2556355643C3019080777 @default.
- W2556355643 hasConceptScore W2556355643C523546767 @default.
- W2556355643 hasConceptScore W2556355643C54355233 @default.
- W2556355643 hasConceptScore W2556355643C71924100 @default.
- W2556355643 hasConceptScore W2556355643C86803240 @default.
- W2556355643 hasLocation W25563556431 @default.
- W2556355643 hasOpenAccess W2556355643 @default.
- W2556355643 hasPrimaryLocation W25563556431 @default.
- W2556355643 hasRelatedWork W1981745416 @default.
- W2556355643 hasRelatedWork W1987856430 @default.
- W2556355643 hasRelatedWork W2030731441 @default.
- W2556355643 hasRelatedWork W2147658767 @default.
- W2556355643 hasRelatedWork W2171147538 @default.
- W2556355643 hasRelatedWork W2284887836 @default.
- W2556355643 hasRelatedWork W2492967488 @default.
- W2556355643 hasRelatedWork W2533909546 @default.
- W2556355643 hasRelatedWork W2588717210 @default.
- W2556355643 hasRelatedWork W2593344193 @default.
- W2556355643 hasRelatedWork W2761690452 @default.
- W2556355643 hasRelatedWork W2810428278 @default.
- W2556355643 hasRelatedWork W2839145311 @default.
- W2556355643 hasRelatedWork W2885924798 @default.
- W2556355643 hasRelatedWork W2896784801 @default.
- W2556355643 hasRelatedWork W2942373062 @default.
- W2556355643 hasRelatedWork W2966300810 @default.
- W2556355643 hasRelatedWork W3011033397 @default.
- W2556355643 hasRelatedWork W3115050222 @default.
- W2556355643 hasRelatedWork W3212291881 @default.
- W2556355643 isParatext "false" @default.
- W2556355643 isRetracted "false" @default.
- W2556355643 magId "2556355643" @default.
- W2556355643 workType "article" @default.